ATE151882T1 - Karzinomverwandtes haptoglobin (hpr) - Google Patents

Karzinomverwandtes haptoglobin (hpr)

Info

Publication number
ATE151882T1
ATE151882T1 AT90902901T AT90902901T ATE151882T1 AT E151882 T1 ATE151882 T1 AT E151882T1 AT 90902901 T AT90902901 T AT 90902901T AT 90902901 T AT90902901 T AT 90902901T AT E151882 T1 ATE151882 T1 AT E151882T1
Authority
AT
Austria
Prior art keywords
hpr
hpr protein
haptoglobin
preparations
marker
Prior art date
Application number
AT90902901T
Other languages
English (en)
Inventor
Francis P Kuhajda
Gary R Pasternack
Original Assignee
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE151882T1 publication Critical patent/ATE151882T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1025Acyltransferases (2.3)
    • C12N9/1029Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015Breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57415Specifically defined cancers of breast
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT90902901T 1989-01-17 1990-01-05 Karzinomverwandtes haptoglobin (hpr) ATE151882T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29772289A 1989-01-17 1989-01-17

Publications (1)

Publication Number Publication Date
ATE151882T1 true ATE151882T1 (de) 1997-05-15

Family

ID=23147472

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90902901T ATE151882T1 (de) 1989-01-17 1990-01-05 Karzinomverwandtes haptoglobin (hpr)

Country Status (10)

Country Link
EP (1) EP0454782B1 (de)
JP (1) JP2959837B2 (de)
KR (1) KR0174528B1 (de)
AT (1) ATE151882T1 (de)
AU (1) AU632535B2 (de)
CA (1) CA2045552C (de)
DE (1) DE69030494T2 (de)
DK (1) DK0454782T3 (de)
ES (1) ES2101695T3 (de)
WO (1) WO1990008324A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4417275A1 (de) * 1994-05-15 1996-02-22 Becker Hans Dieter Dr Verfahren und Kit zur Tumorprognose, -diagnostik und -prophylaxe
US6531277B2 (en) 1994-10-25 2003-03-11 The Curators Of The University Of Missouri Endometriosis-specific secretory protein
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
BE1010935A7 (nl) * 1997-02-19 1999-03-02 Delanghe Joris Richard Siegfri Fenotypering van humaan haptoglobine in serum of plasma door middel van quantitatieve agglutinatie met streptococcus antigenen.
GB0000901D0 (en) * 2000-01-14 2000-03-08 Isis Innovation Antiparasitic agent
JP4706093B2 (ja) * 2000-09-25 2011-06-22 富士レビオ株式会社 パルボウイルスの除去方法及び精製方法
CN1871362A (zh) * 2003-09-05 2006-11-29 皇家妇女医院 卵巢癌的诊断标记物
DE102010008644A1 (de) 2010-02-15 2011-08-18 Bayer Schering Pharma Aktiengesellschaft, 13353 Zyklische Ketoenole zur Therapie
DE102011011040A1 (de) 2011-02-08 2012-08-09 Bayer Pharma Aktiengesellschaft (5s,8s)-3-(4'-Chlor-3'-fluor-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-on (Verbindung A) zur Therapie
JP2014508752A (ja) 2011-02-17 2014-04-10 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 治療用の置換3−(ビフェニル−3−イル)−8,8−ジフルオロ−4−ヒドロキシ−1−アザスピロ[4.5]デカ−3−エン−2−オン
DE102011080405A1 (de) 2011-08-04 2013-02-07 Bayer Pharma AG Substituierte 3-(Biphenyl-3-yl)-8,8-difluor-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-one zur Therapie
DE102011080406A1 (de) 2011-08-04 2013-02-07 Bayer Pharma AG Substituierte 3-(Biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro8[4.5]dec-3-en-2-one
WO2017204295A1 (ja) * 2016-05-27 2017-11-30 和光純薬工業株式会社 消化器癌の判定方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946774A (en) * 1987-11-09 1990-08-07 Trustees Of Boston University Process for detecting cancer and for monitoring the effectiveness of cancer therapy

Also Published As

Publication number Publication date
DK0454782T3 (da) 1997-10-27
DE69030494D1 (de) 1997-05-22
CA2045552C (en) 2002-10-29
AU5040690A (en) 1990-08-13
WO1990008324A1 (en) 1990-07-26
AU632535B2 (en) 1993-01-07
EP0454782A1 (de) 1991-11-06
JP2959837B2 (ja) 1999-10-06
CA2045552A1 (en) 1990-07-26
EP0454782B1 (de) 1997-04-16
KR910700463A (ko) 1991-03-15
ES2101695T3 (es) 1997-07-16
DE69030494T2 (de) 1997-08-07
JPH04504110A (ja) 1992-07-23
KR0174528B1 (ko) 1999-05-15

Similar Documents

Publication Publication Date Title
JPS6447392A (en) Monoclonal antibody
NO175944C (no) Monoklonale antistoffer for anvendelse til in vitro påvisning av tumorassosiert mucinantigen, og hybridomcellelinjer som produserer disse
ATE151882T1 (de) Karzinomverwandtes haptoglobin (hpr)
FI92258B (fi) Onkostatiini-A:n käyttö diagnostisessa menetelmässä
AU3066489A (en) Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
ES2061730T3 (es) Nuevos anticuerpos.
DE68925226D1 (de) Monoklonale Antikörper
DE69535719D1 (de) Fas-antigenbindender ligand
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
DK0687295T3 (da) Human B-lymfoblastoidcellelinje, der secernerer anti-gangliosid-antistof
AU555699B2 (en) Pp13 protein from placenta
ATE70280T1 (de) Charakteristische polypeptide und antikoerper vom papillomavirus, diagnostische verfahren und dieselben verwendende impfungen.
GB2182949A (en) Monoclonal antibodies and antigens for human non-small cell lung carcinomas
EP0109434A4 (de) In vitro diagnoseverfahren unter verwendung von monoklonalen antikörpern gegen konnektive gewebeproteine.
DK0466818T3 (da) Monoklonalt antistof der genkender et glycoprotein fra mucin-antigen fra membranen af fedtkugler fra human mælk
SE8900899L (sv) Peptider foer diagnostisk anvaendning
ES8504257A1 (es) Un metodo para determinar antigenos estreptococales en una muestra clinica
Karamova et al. Conformational variants of human alpha-fetoprotein
JPS5686194A (en) Novel protein and its manufacture
EP0282018A3 (en) Process for isolating basal membrane proteins from human or animal tissues
ATE58397T1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
FI885025A0 (fi) Koagulationshaemmande protein pp4-x, dess framstaellning och anvaendning.
DE3879684D1 (de) Von protein ps2 abgeleitete peptide.
EP0095502A4 (de) Menschliche monoklonale antikörper oder lymphokinen bei der abscheidung von zellen oder der diagnose von brustkrebs.
Ohkawa et al. An improved sensitive assay method for the heterogeneity of α-foetoprotein: possible application for early differential diagnosis

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee